Claims
- 1. A compound which is selected from those of formula (I) : ##STR21## in which : A represents a --CH.sub.2 --CH.sub.2 -- chain, unsubstituted or substituted with lower alkyl,
- R.sub.1 represents hydrogen or lower alkyl,
- R.sub.2 represents hydrogen, halogen, or lower alkyl,
- R.sub.3 and R.sub.4, together with the benzene ring which carries them, form a ring-system E.sub.3 chosen from : benzothiophene, benzofuran, and benzodioxane, on the understanding that the portion of the ring-system E.sub.3 formed by R.sub.3 and R.sub.4 and the two carbon atoms of the benzene ring which carry them is :
- unhydrogenated or partially hydrogenated,
- and unsubstituted or substituted with one or more radicals chosen from : halogen, hydroxyl, lower alkyl, lower alkoxy, lower alkoxycarbonyl, and trifluoromethyl,
- R.sub.5 represents hydrogen or lower alkyl,
- R.sub.6 represents a group ##STR22## in which X represents oxygen and R.sub.7 represents a radical chosen from :
- lower alkyl, unsubstituted or substituted with one or more radicals chosen from halogen, hydroxyl, and lower alkoxy,
- linear or branched alkenyl having 2 to 7 carbon atoms, inclusive, unsubstituted or substituted with one or more radicals chosen from halogen, hydroxyl, and lower alkoxy, and --(CH.sub.2).sub.m -E.sub.4 in which m represents 0 or 1 to 4, inclusive, and E.sub.4 represents a mono- or bicyclic cycloalkyl having 3 to 12 carbon atoms, inclusive, unsubstituted or substituted with one or more radicals chosen from halogen, and lower alkyl, optical isomers,
- and its addition salts thereof with a pharmaceutically-acceptable acid or base when R.sub.3 or R.sub.4 represents a salifiable group,
- on the understanding that the terms "lower alkyl" and "lower alkoxy" denote linear or branched groups having 1 to 6 carbon atoms, inclusive, and that the terms "cycloalkenyl" and "alkenyl" denote hydrocarbon groups containing one or more double bonds.
- 2. A compound as claimed in claim 1 in which R.sub.1 represents a methyl radical.
- 3. A compound as claimed in claim 1 in which R.sub.3 and R.sub.4, together with the benzene ring which carries them, form a ring-system E.sub.3 chosen from: benzofuran, and benzodioxane, on the understanding that the portion of the ring-system E.sub.3 formed by R.sub.3 and R.sub.4 and the 2 carbon atoms of the benzene ring which carry them is :
- unhydrogenated or partially hydrogenated,
- and unsubstituted or substituted with one or more radicals chosen from: halogen, hydroxyl, lower alkyl, lower alkoxy, lower alkoxycarbonyl and trifluoromethyl.
- 4. A compound as claimed in claim 1 in which R.sub.3 and R.sub.4, together with the benzene ring which carries them, form a benzodioxane, on the understanding that the benzene ring formed by R.sub.3, R.sub.4 and the 2 carbon atoms which carry them is unsubstituted or substituted with one or more radicals chosen from halogen, hydroxyl, lower alkyl, lower alkoxy, lower alkoxycarbonyl, and trifluoromethyl.
- 5. A compound as claimed in claim 1 in which R.sub.1 represents a methyl radical and R.sub.3 and R.sub.4, together with the benzene ring which carries them, form a benzofuran on the understanding that the benzene ring formed by R.sub.3 and R.sub.4 and the 2 carbon atoms which carry them is unsubstituted or substituted with one or more radicals chosen from: halogen, hydroxyl, lower alkyl, lower alkoxy, lower alkoxycarbonyl, and trifluoromethyl.
- 6. A pharmaceutical composition containing as active principle a compound as claimed in claim 1, in combination with one or more pharmaceutically-acceptable excipients.
- 7. A method of treating a mammal afflicted with a sleep disorder comprising the step of administering to the said mammal an amount of a compound as claimed in claim 1 which binds at melatonin receptors and is effective in the treatment of said disorder.
- 8. A compound as claimed in claim 1 which is N-�2-(6-methoxy-1,4-benzodioxan-5-yl)ethyl!acetamide.
- 9. A compound as claimed in claim 1 which is N-�2-(6-methoxy-3-methylbenzofuran-7-yl)ethyl!acetamide.
Priority Claims (1)
Number |
Date |
Country |
Kind |
92 11671 |
Oct 1992 |
FRX |
|
Parent Case Info
The present application is a division of prior-filed application Ser. No. 08/446,409, filed May 22, 1995, now U.S. Pat. No. 5,554,642 which is a division of our prior-filed application Ser. No. 08/375,503, filed Jan. 18, 1995, now U.S. Pat. No. 5,464,872, which in turn is a continuation of our prior-filed application Ser. No. 08/131,207, filed Oct. 1, 1993, now abandoned.
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
5059620 |
Stout et al. |
Oct 1991 |
|
5194614 |
Andriewx et al. |
Mar 1993 |
|
5225442 |
Andrieux et al. |
Jul 1993 |
|
Foreign Referenced Citations (1)
Number |
Date |
Country |
0238868 |
Sep 1987 |
EPX |
Divisions (2)
|
Number |
Date |
Country |
Parent |
446409 |
May 1995 |
|
Parent |
375503 |
Jan 1995 |
|
Continuations (1)
|
Number |
Date |
Country |
Parent |
131207 |
Oct 1993 |
|